The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

Abstract

Objective: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D.

Research design and methods: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors.

Results: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all).

Conclusions: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Autoantibodies / metabolism
  • Biomarkers / metabolism
  • Blood Glucose / metabolism
  • C-Peptide / metabolism
  • Diabetes Mellitus, Type 1 / metabolism
  • Diabetes Mellitus, Type 1 / prevention & control*
  • Disease Progression
  • Female
  • Glucose Tolerance Test
  • Humans
  • Hyperglycemia / diagnosis*
  • Male
  • Patient Acuity
  • Risk Factors
  • Severity of Illness Index

Substances

  • Autoantibodies
  • Biomarkers
  • Blood Glucose
  • C-Peptide